Cited by 780HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Open access

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.·2018·Nature

DOI 10.1038/nature25475PMC PMC5808581

Open this paper in CoChat — free account

Abstract

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature25475

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777

Show all 54 references

Sorted by citations

Items 201–300 of 779

A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer
Son, J., Jang, J., Beyett, T. S., Eum, Y., Haikala, H. M., Verano, A. L., Lin, M., Hatcher, J. M., Kwiatkowski, N. P., Eser, P. Ö., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2693 · Cited by 47
HER2 targeted therapy in colorectal cancer: New horizons
Suwaidan, A. A., Lau, D. K., & Chau, I. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102363 · Cited by 45
HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
Yu, X., Ji, X., & Su, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860313 · Cited by 45
Genetic interactions reveal distinct biological and therapeutic implications in breast cancer
Lin, C., Jin, X., Ma, D., Chen, C., Ou-Yang, Y., Pei, Y., Zhou, C., Qu, F., Wang, Y., Liu, C., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.006 · Cited by 44
Clinical tumour sequencing for precision oncology: time for a universal strategy
Cheng, M. L., Berger, M. F., Hyman, D. M., & Solit, D. B. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0043-2 · Cited by 42
Self-citation
HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment
Li, J., Xiao, Q., Bao, Y., Wang, W., Goh, J. Y., Wang, P., & Yu, Q. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1624113 · Cited by 42
Variance prior specification for a basket trial design using Bayesian hierarchical modeling
Cunanan, K. M., Iasonos, A. E., Shen, R., & Gönen, M. (2018) · Clinical Trials · doi:10.1177/1740774518812779 · Cited by 41
Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer
Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316607 · Cited by 45
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Gou, Q., Gou, Q., Gan, X., & Xie, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-61087-2 · Cited by 42
Identification of Four Immune Subtypes in Bladder Cancer Based on Immune Gene Sets
Tang, C., Ma, J., Liu, X., & Liu, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.544610 · Cited by 40
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers
Jhaveri, K. L., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2657 · Cited by 40
Self-citation
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
Yang, G., Xu, H., Yang, Y., Zhang, S., Xu, F., Hao, X., Li, J., Xing, P., Hu, X., Liu, Y., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02470-6 · Cited by 39
Self-citation
Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers
Hu, M., Li, Y., Li, J., Zhou, H., Liu, C., Liu, Z., Gong, Y., Ying, B., & Xie, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114775 · Cited by 40
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3558 · Cited by 38
Emerging importance of HER3 in tumorigenesis and cancer therapy
Garrett, J. T., Tendler, S., Feroz, W., Kilroy, M. K., & Yu, H. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01008-y · Cited by 37
Rates ofERBB2Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in anERBB2-Amplified Acral Melanoma
Gottesdiener, L. S., O'Connor, S., BUSAM, K. J., Won, H. H., Solit, D. B., Hyman, D. M., & Shoushtari, A. N. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1397 · Cited by 38
Self-citation
Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
Maria, B., Sims, A. H., & Simon, P. L. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0062 · Cited by 37
Discovery through clinical sequencing in oncology
Donoghue, M. T. A., Schram, A. M., Hyman, D. M., & Taylor, B. S. (2020) · Nature Cancer · doi:10.1038/s43018-020-0100-0 · Cited by 38
Self-citation
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial
Zañudo, J. G. T., Barroso‐Sousa, R., Jain, E., Jin, Q., Li, T., Buendia-Buendia, J. E., Pereslete, A., Abravanel, D. L., Ferreira, A. R., Wrabel, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45835-6 · Cited by 37
Molecular Testing in Breast Cancer
Sun, L., Wu, A. S.-H., Bean, G. R., Hagemann, I. S., & Lin, C. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.07.026 · Cited by 37
Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2
Liu, Z., Sang, X., Wang, M., Liu, Y., Liu, J., Wang, X., Liu, P., & Cheng, H.-L. M. (2021) · Oncogene · doi:10.1038/s41388-021-02015-w · Cited by 39
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
Liu, B., Yi, Z., Guan, Y., Ouyang, Q., Li, C., Guan, X., Lv, D., Li, L., Zhai, J., Qian, H., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4652 · Cited by 35
Targeting ERBB2 mutations in solid tumors: biological and clinical implications
Cousin, S., Khalifa, E., Crombé, A., Laizet, Y., Lucchesi, C., Toulmonde, M., Moulec, S. L., Auzanneau, C., Soubeyran, I., & Italiano, A. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0630-4 · Cited by 35
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Chan, T., Chin, Y. M., & Low, S. (2019) · Oncology and Therapy · doi:10.1007/s40487-018-0090-6 · Cited by 36
Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers
Kopetz, S., Shaw, K. R. M., Lee, J. J., Zhang, J., Litzenburger, B. C., Holla, V. R., Kinyua, W. K., Broaddus, E., Daniels, M. S., Meric‐Bernstam, F., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00213 · Cited by 35
Self-citation
Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial
Mortimer, J. E., Palma, J. D., Schmid, K. K., Ye, Y., & Jahanzeb, M. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1112-5 · Cited by 35
Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer
Nelakurti, D. D., Pappula, A. L., Rajasekaran, S., Miles, W. O., & Petreaca, R. C. (2020) · Cancers · doi:10.3390/cancers12092616 · Cited by 35
Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress
Rosner, S., Valdivia, A., Hoe, H. J., Murray, J. C., Levy, B. P., Felip, E., & Solomon, B. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389968 · Cited by 35
Cancer Treatment in the Genomic Era
Doherty, G. J., Petruzzelli, M., Beddowes, E. J., Ahmad, S. S., Caldas, C., & Gilbertson, R. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-011840 · Cited by 36
Targeting HER2 genomic alterations in non-small cell lung cancer
Zeng, J., Ma, W., Young, R. B., & Li, T. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.04.001 · Cited by 37
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Sentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 34
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023
Thill, M., Kolberg‐Liedtke, C., Albert, U., Banys-Paluchowski, M. J., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Ditsch, N., Fallenberg, E. M., et al. (2023) · Breast Care · doi:10.1159/000531579 · Cited by 34
HER2 and urothelial carcinoma: current understanding and future directions
Raggi, D., Crupi, E., Pederzoli, F., Martini, A., Briganti, A., Alhalabi, O., O’Donnell, P. H., Ross, J. S., Gupta, S., Kamat, A. M., et al. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01075-x · Cited by 33
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 33
Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine
Horak, P., Leichsenring, J., Goldschmid, H., Kreutzfeldt, S., Kazdal, D. N., Teleanu, V., Endris, V., Gieldon, L., Allgäuer, M., Volckmar, A., et al. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22987 · Cited by 34
Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue
Loria, R., Vici, P., Lisa, F. S. D., Soddu, S., Maugeri‐Saccà, M., & Bon, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877380 · Cited by 34
Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
Albarrán, V., Rosero, D. I., Chamorro, J. V., Pozas, J., Román, M. S., Barrill, A. M., Alía, V., Sotoca, P., Guerrero, P., Calvo, J. C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012659 · Cited by 33
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
Ascione, L., Crimini, E., Trapani, D., Marra, A., Criscitiello, C., & Curigliano, G. (2023) · The Oncologist · doi:10.1093/oncolo/oyad246 · Cited by 35
Heterogeneity of genomic profile in patients with HER2-positive breast cancer
Chen, B., Zhang, G., Wei, G., Wang, Y., Guo, L., Lin, J., Li, K., Mok, H., Cao, L., Ren, C., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0414 · Cited by 33
Biomarker discovery with quantum neural networks: a case-study in CTLA4-activation pathways
Nguyen, P.-N. (2024) · BMC Bioinformatics · doi:10.1186/s12859-024-05755-0 · Cited by 38
The Dilemma of HER2 Double-equivocal Breast Carcinomas
Marchiò, C., Dell’Orto, P., Annaratone, L., Geyer, F. C., Venesio, T., Berrino, E., di Cantogno, L. V., Garofoli, A., Rangel, N., Casorzo, L., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001100 · Cited by 32
ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high‐risk characteristics by molecular expression profiling
Christgen, M., Bartels, S., Radner, M., Raap, M., Rieger, L., Christgen, H., Gluz, O., Nitz, U. A., Harbeck, N., Lehmann, U., et al. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22716 · Cited by 32
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
Medford, A. J., Dubash, T. D., Juric, D., Spring, L. M., Niemierko, A., Vidula, N., Peppercorn, J. M., Isakoff, S. J., Reeves, B. A., LiCausi, J. A., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0090-5 · Cited by 32
Self-citation
HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer
Mazumder, A., Shiao, S. L., & Haricharan, S. (2021) · Endocrinology · doi:10.1210/endocr/bqab153 · Cited by 32
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
Ríos-Hoyo, A., Moliner, L., & Arriola, E. (2022) · Cancers · doi:10.3390/cancers14081931 · Cited by 32
Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives
Boch, T., Köhler, J., Janning, M., & Loges, S. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0540 · Cited by 32
Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre
Scheiter, A., Hierl, F., Lüke, F., Keil, F., Heudobler, D., Einhell, S., Klier-Richter, M., Konstandin, N. P., Weber, F., Scheiter, A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02120-x · Cited by 32
Novel Functionalized Spiro [Indoline-3,5′-pyrroline]-2,2′dione Derivatives: Synthesis, Characterization, Drug-Likeness, ADME, and Anticancer Potential
Asif, M., Alvi, S. S., Azaz, T., Khan, A. R., Tiwari, B., Hafeez, B. B., & Nasibullah, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087336 · Cited by 32
HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities
Ismail, A., Desai, A. P., & Boumber, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1624124 · Cited by 31
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation
Athauda, A., Fong, C., Lau, D. K., Javle, M. M., Abou‐Alfa, G. K., Morizane, C., Steward, K., & Chau, I. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101998 · Cited by 31
New insights into ErbB3 function and therapeutic targeting in cancer
Hafeez, U., Parslow, A. C., Gan, H. K., & Scott, A. M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1829485 · Cited by 31
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study
Bujak, A. Z., Weng, C.-F., Silva, M. J., Yeung, M. M., Lo, L. L., Ftouni, S., Litchfield, C., Ko, Y.-A., Kuykhoven, K. S., van Geelen, C. T., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003363 · Cited by 33
Self-citation
Neratinib in HER2-Positive Breast Cancer Patients
Paranjpe, R., Basatneh, D., Tao, G., Angelis, C. D., Noormohammed, S., Ekinci, E., Abughosh, S., Ghose, R., & Trivedi, M. V. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028018824088 · Cited by 31
Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma
Peng, J., Zou, D., 龚五星, Kang, S., & Han, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1734156 · Cited by 31
GC–MS based comparative metabolomic analysis of MCF-7 and MDA-MB-231 cancer cells treated with Tamoxifen and/or Paclitaxel
Semreen, M. H., Alniss, H. Y., Cacciatore, S., El-Awady, R., Mousa, M., Almehdi, A. M., El‐Huneidi, W., Zerbini, L. F., & Soares, N. C. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103875 · Cited by 30
Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling
Madison, R. W., Schrock, A. B., Castellanos, E. H., Gregg, J. P., Snider, J. W., Ali, S. M., Miller, V. A., Singal, G., Alexander, B. M., Venstrom, J. M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.033 · Cited by 30
Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer
Si, X., Pan, R., Ma, S., Li, L., Liang, L., Zhang, P., Chu, Y.-P., Wang, H., Wang, M., Zhang, X., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13757 · Cited by 30
The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
Qin, H., & Patel, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062916 · Cited by 30
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Bedard, P. L., Li, S., Wisinski, K. B., Yang, E. S.-H., Limaye, S. A., Mitchell, E. P., Zwiebel, J. A., Moscow, J. A., Gray, R. J., Wang, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00165 · Cited by 30
Self-citation
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology
Martín-Romano, P., Mezquita, L., Hollebecque, A., Lacroix, L., Rouleau, É., Gazzah, A., Bahleda, R., Planchard, D., Varga, A., Baldini, C., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00484 · Cited by 32
Precision oncology: current and future platforms for treatment selection
Tang, X., Berger, M. F., & Solit, D. B. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.009 · Cited by 32
Self-citation
A paradigm shift in biomarker guided oncology drug development
Jørgensen, J. T. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.03.36 · Cited by 29
Canine models of human cancer: Bridging the gap to improve precision medicine
Nance, R. L., Sajib, A. M., & Smith, B. F. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.12.003 · Cited by 29
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
Marín, A., Mamun, A. A., Patel, H. M., Akamatsu, H., Ye, D., Sudhan, D. R., Eli, L. D., Marcelain, K., Brown, B. P., Meiler, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3617 · Cited by 30
Self-citation
Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China
Xu, F., Yang, G., Xu, H., Yang, L., Qiu, W., Li, J., & Wang, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13317 · Cited by 29
Self-citation
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
Friedman, C. F., D'souza, A., Roufai, D. B., Tinker, A. V., Miguel, M. J. D., Gambardella, V., Goldman, J. W., Loi, S., Melisko, M., Oaknin, A., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.12.004 · Cited by 28
Self-citation
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Okines, A. F. C., Curigliano, G., Mizuno, N., Oh, D., Rorive, A., Soliman, H. H., Takahashi, S., Bekaii‐Saab, T., Burkard, M. E., Chung, K. Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03462-0 · Cited by 30
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Siegel, F., Siegel, S., Kotýnková, K., Uzunbas, G. K., Korr, D., Tomono, H., Andersen, S., Denney, D. R., Berger, M., Schulze, V., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0605 · Cited by 28
Self-citation
Developing Precision Medicine for Bladder Cancer
Guercio, B. J., Iyer, G., & Rosenberg, J. E. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.02.008 · Cited by 30
Self-citation
HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models
Gameiro, A., Nascimento, C., Correia, J., & Ferreira, F. (2021) · Cancers · doi:10.3390/cancers13092007 · Cited by 28
Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study
Blackwell, K., Zaman, K., Qin, S., Tkaczuk, K. H. R., Campone, M., Hunt, D., Bryce, R. P., & Goldstein, L. J. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.12.011 · Cited by 27
Self-citation
Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Roy, R., Winteringham, L. N., Lassmann, T., & Forrest, A. R. R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0273 · Cited by 28
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review
Vaghi, C., Mauri, G., Agostara, A. G., Patelli, G., Pizzutilo, E. G., Nakamura, Y., Yoshino, T., Siena, S., & Bianchi, A. S. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102488 · Cited by 28
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
Dişel, U., Madison, R. W., Abhishek, K., Chung, J., Trabucco, S. E., Matos, A. O., Frampton, G. M., Albacker, L. A., Reddy, V. P., Karadurmuş, N., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0528 · Cited by 27
Extramammary Paget’s disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies
Maeda, T., Kitamura, S., Nishihara, H., & Yanagi, T. (2020) · Oncogene · doi:10.1038/s41388-020-01404-x · Cited by 27
Reporting on invasive lobular breast cancer in clinical trials: a systematic review
Baelen, K. V., Cauwenberge, J. V., Maetens, M., Beck, G., Camden, A., Chase, M.-C., Fraser, V. L., Freeney, S., Hutcheson, L., Levine, J. K., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00627-5 · Cited by 26
The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
Lamarca, Á., Galdy, S., Barriuso, J., Moghadam, S., Beckett, E., Rogan, J., Backen, A. C., Billington, C., McNamara, M. G., Hubner, R. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206007 · Cited by 26
Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma
Shamir, E. R., Chen, Y., & Krings, G. (2020) · Modern Pathology · doi:10.1038/s41379-019-0449-8 · Cited by 26
Genomic Alteration in Metastatic Breast Cancer and Its Treatment
Li, A., Schleicher, S. M., André, F., & Mitri, Z. I. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280463 · Cited by 26
Efficacy of targeted therapy in patients with HER2‐positive non‐small cell lung cancer: A systematic review and meta‐analysis
Wu, H., Zhuo, K., & Wang, K. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15155 · Cited by 26
Ex Vivo Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized Medicine
Taverna, J. A., Hung, C., Williams, M. H., Williams, R., Chen, M., Kamali, S., Sambandam, V., Chiu, C. H.-L., Osmulski, P. A., Gaczynska, M. E., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2024.107533 · Cited by 26
Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression
Li, Z., Shao, C., Liu, X., Lu, X., Jia, X., Zheng, X., Wang, S., Zhu, L., Li, K., Pang, Y., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz086 · Cited by 26
Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers
Gopal, P., Sarihan, E. I., Chie, E. K., Kuzmishin, G. B., Doken, S., Pennell, N. A., Raymond, D. P., Murthy, S. C., Ahmad, U., Raja, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13161-x · Cited by 26
Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma
Gambardella, V., Fleitas, T., Tarazona, N., Cejalvo, J. M., Gimeno-Valiente, F., Martínez‐Ciarpaglini, C., Huerta, M., Roselló, S., Castillo, J., Roda, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz143 · Cited by 25
Integrating proteomics into precision oncology
Wahjudi, L. W., Bernhardt, S., Abnaof, K., Horak, P., Kreutzfeldt, S., Heining, C., Borgoni, S., Becki, C., Berg, D., Richter, D., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33301 · Cited by 25
Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
Koyama, K., Ishikawa, H., Abe, M., Shiose, Y., Ueno, S., Qiu, Y., Nakamaru, K., & Murakami, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267027 · Cited by 25
The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
Keup, C., Kimmig, R., & Kasimir‐Bauer, S. (2023) · Cancers · doi:10.3390/cancers15225463 · Cited by 25
Dynamic genome and transcriptional network‐based biomarkers and drugs: precision in breast cancer therapy
Kyrochristos, I. D., Ziogas, D. E., & Roukos, D. H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21549 · Cited by 25
Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance
Bose, R., & Ma, C. X. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2110552 · Cited by 25
HER2: defining a Neu target in non-small-cell lung cancer
Ekman, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz043 · Cited by 24
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology
Rohrberg, K. S., & Lassen, U. (2021) · Drugs · doi:10.1007/s40265-020-01459-w · Cited by 25
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations
Conforti, F., Pala, L., Pagan, E., Guerini‐Rocco, E., Bagnardi, V., Montagna, E., Peruzzotti, G., Pas, T. M. D., Fumagalli, C., Pileggi, S., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.06.011 · Cited by 24
Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision
Zhang, Y., Esmail, A., Mazzaferro, V., & Abdelrahim, M. (2022) · Cancers · doi:10.3390/cancers14205074 · Cited by 24
SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics
Singer, F., Irmisch, A., Toussaint, N. C., Grob, L., Singer, J., Thurnherr, T., Beerenwinkel, N., Levesque, M. P., Dummer, R., Quagliata, L., et al. (2018) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-018-0680-0 · Cited by 23
Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas
Harthimmer, M. R., Stolborg, U., Pfeiffer, P., Mortensen, M. B., Fristrup, C. W., & Detlefsen, S. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205912 · Cited by 23
NGS in Lung, Breast, and Unknown Primary Cancer in Colombia: A Multidisciplinary Consensus on Challenges and Opportunities
Mantilla, W. A., Sanabria‐Salas, M. C., Baldión, A. M., Sua, L. F., Gonzalez, D. M., & Lema, M. (2021) · JCO Global Oncology · doi:10.1200/go.21.00046 · Cited by 25
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022
Thill, M., Lüftner, D., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2022) · Breast Care · doi:10.1159/000524789 · Cited by 23
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
Ishiyama, N., O'Connor, M., Salomatov, A., Romashko, D., Thakur, S., Mentes, A., Hopkins, J. F., Frampton, G. M., Albacker, L. A., Kohlmann, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-0940 · Cited by 22
Frequency of genetic alterations differs in advanced breast cancer between metastatic sites
Grote, I., Poppe, A., Lehmann, U., Christgen, M., Kreipe, H. H., & Bartels, S. (2023) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23199 · Cited by 24
The Status and Impact of Clinical Tumor Genome Sequencing
Shaw, K. R. M., & Maitra, A. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015034 · Cited by 22

Authors: Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J., Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler Jr, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J., & Solit, D. B.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
The University of Texas MD Anderson Cancer Center (US)
Vall d'Hebron Hospital Universitari (ES)
Dana-Farber Cancer Institute (US)
USC Norris Comprehensive Cancer Center (US)
Vanderbilt University (US)
Peter MacCallum Cancer Centre (AU)
Washington University in St. Louis (US)
Puma Biotechnology (United States) (US)
Corresponding author: Hyman, David M.
ORCID: Hyman, David M.
Piha-Paul, Sarina A.
Won, Helen
Rodon, Jordi
Saura, Cristina
Shapiro, Geoffrey I.
Juric, Dejan
Quinn, David I.
Mayer, Ingrid A.
Boni, Valentina
Calvo, Emiliano
Loi, Sherene
Lockhart, Albert C.
Erinjeri, Joseph P.
Scaltriti, Maurizio
Ulaner, Gary A.
Patel, Juber
Bouvier, Nancy
Murali, Rajmohan
Schram, Alison M.
Smyth, Lillian M.
Jhaveri, Komal
Li, Bob T.
Drilon, Alexander
Harding, James J.
Iyer, Gopa
Taylor, Barry S.
Berger, Michael F.
Xu, Feng
Eli, Lisa D.
Lalani, Alshad S.
Bryce, Richard P.
Arteaga, Carlos L.
Solit, David B.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2018-01-31
Volume: 554
Issue: 7691
Pages: 189-194
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature25475
PMC: PMC5808581
OpenAlex: W2785610956
Cited by: 780
References: 54
Citations by year: 2026: 40 · 2025: 64 · 2024: 89 · 2023: 99 · 2022: 113 · 2021: 103 · 2020: 113 · 2019: 86 · 2018: 69
FWCI: 34.53
Type: journal article
Language: en
Update notices: correction (2019-02-12)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Funders: Puma Biotechnology
National Institutes of Health (UL1TR000371)
National Cancer Institute (R01CA204749, U01CA180964, R01CA080195, P50CA098131, P30CA008748, P30CA016672, T32CA009207, R25CA020449, P30CA014089)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, ERBB2, HER3, neratinib, basket trials, breast cancer, biliary tract cancer, cervical cancer, targeted therapy
MeSH terms: Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Quinolines, Cohort Studies, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Mutation, Missense, Receptor, ErbB-3, Protein Kinase Inhibitors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks